AI Drug Discovery
Most compounds do not fail on potency
USD 90–260K · 12–24 weeks of retained design cycles · Optimised designs with predicted property profiles
At a glance
- Price band
- USD 90–260K
- Duration
- 12–24 weeks
- Structure
- Retained design cycles
- Add-on
- In-vitro ADME
Indicative list price. Final scope and price confirmed in the proposal.
Talk to a scientistThe problem
Why teams buy this
Compounds that look excellent on potency fail late on solubility, permeability, metabolic stability or toxicity. Late-stage attrition is the most expensive category of failure in discovery - and it is largely predictable if you look early enough.
What you get
Deliverables, not activity
- Optimised compound designs with predicted property profiles
- An ADMET and liability risk report, including the liabilities you did not ask about
- Structure–activity relationship analysis across your series
- A synthesis prioritisation list your chemists can act on
- Optional: in-vitro ADME confirmation of the selected compounds
How it works
The sequence
Baseline profilingMulti-parameter optimisation (generative + QSAR)Synthetic accessibility and IP-space filteringPrioritised designs per cycleIn-vitro confirmation
Delivered as retained design cycles that fit your chemistry cadence.
Who this is for
Biotech lead-optimisation teams · pharma discovery programmes · chemistry CROs needing a computational partner.
Proof
Representative result
Four optimisation cycles improving predicted oral bioavailability and removing an hERG liability while holding sub-100 nM potency.
Representative programme - illustrates typical scope and outcomes; not an individual client account. Client-specific references are available on request under confidentiality.
Enterprise AI for Life Sciences
Ready to Advance Your Drug Discovery Pipeline?
Partner with Prognica Labs to leverage enterprise-grade AI, computational chemistry, and molecular simulation technologies that accelerate discovery, reduce development risk, and improve R&D productivity.
From biotech startups to global pharmaceutical organizations, we help research teams make faster, evidence-driven decisions across every stage of early drug discovery.